Components of metabolic syndrome increase the risk of mortality in nonalcoholic fatty liver disease (NAFLD)

Medicine (United States)

Volumn 97, Issue 13, 2018, Pages

  Golabi, Pegah ^a   Otgonsuren, Munkhzul ^a   De Avila, Leyla ^a   Sayiner, Mehmet ^b   Rafiq, Nila ^a,b   Younossi, Zobair M ^a,b  

^a BETTY AND GUY BEATTY CENTER FOR INTEGRATED RESEARCH   (United States)

^b Center for Liver Diseases   (United States)

Author keywords

metabolic syndrome; mortality; NAFLD

Indexed keywords

ADULT; ARTICLE; BODY MASS; CARDIOVASCULAR MORTALITY; DIABETES MELLITUS; DISEASE ASSOCIATION; FEMALE; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; MORTALITY RISK; NONALCOHOLIC FATTY LIVER; OUTCOME ASSESSMENT; PRIORITY JOURNAL; SELF REPORT; AGE DISTRIBUTION; CARDIOVASCULAR DISEASE; COMORBIDITY; DIAGNOSTIC IMAGING; MIDDLE AGED; MORTALITY; NUTRITION; PROPORTIONAL HAZARDS MODEL; RISK FACTOR; SEX RATIO; UNITED STATES;

ADULT; AGE DISTRIBUTION; BODY MASS INDEX; CARDIOVASCULAR DISEASES; COMORBIDITY; FEMALE; HUMANS; INSULIN RESISTANCE; MALE; METABOLIC SYNDROME; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; NUTRITION SURVEYS; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; SEX DISTRIBUTION; UNITED STATES;

EID: 85045130942     PISSN: 00257974     EISSN: 15365964     Source Type: Journal    
DOI: 10.1097/MD.0000000000010214     Document Type: Article

References (48)

1. Bellentani S. The epidemiology of non-alcoholic fatty liver disease. Liver Int 2017;37(Suppl 1):81-4.
2. Sayiner M, Koenig A, Henry L, et al. Epidemiology of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis in the United States and the rest of the world. Clin Liver Dis 2016;20:205-14.
3. Younossi ZM, Koenig AB, Abdelatif D, et al. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 2016;64:73-84.
4. Fazel Y, Koenig AB, Sayiner M, et al. Epidemiology and natural history of non-alcoholic fatty liver disease. Metabolism 2016;65:1017-25.
5. Goh GB, McCullough AJ. Natural history of nonalcoholic fatty liver disease. Dig Dis Sci 2016;61:1226-33.
6. Calzadilla Bertot L, Adams LA. The natural course of non-alcoholic fatty liver disease. Int J Mol Sci 2016;17: E774. DOI: 10.3390/ijms17050774.
7. Kim NH, Park J, Kim SH, et al. Non-alcoholic fatty liver disease, metabolic syndrome and subclinical cardiovascular changes in the general population. Heart 2014;100:938-43.
8. Vernon G, Baranova A, Younossi ZM. Systematic review: The epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther 2011;34:274-85.
9. National Cholesterol Education Program. Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Adult Treatment Panel III: Full Report. Bethesda, MD: National Institute of Health; 2001. NIH Publication No. 01-3670. 2001.
10. Grundy SM, Brewer HBJr, Cleeman JI, et al. Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 2004;109:433-8.
11. Eckel RH, Alberti KG, Grundy SM, et al. The metabolic syndrome. Lancet 2010;375:181-3.
12. Younossi ZM, Henry L. Economic and quality-of-life implications of non-alcoholic fatty liver disease. Pharmacoeconomics 2015;33:1245-53.
13. Younossi ZM, Blissett D, Blissett R, et al. The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe. Hepatology 2016;64:1577-86.
14. Sayiner M, Stepanova M, Pham H, et al. Assessment of health utilities and quality of life in patients with non-alcoholic fatty liver disease. BMJ Open Gastroenterol 2016;3:e000106.
15. Golabi P, Otgonsuren M, Cable R, et al. Non-alcoholic Fatty Liver Disease (NAFLD) is associated with impairment of Health Related Quality of Life (HRQOL). Health Qual Life Outcomes 2016;14:18.
16. Stepanova M, Rafiq N, Makhlouf H, et al. Predictors of all-cause mortality and liver-related mortality in patients with non-alcoholic fatty liver disease (NAFLD). Dig Dis Sci 2013;58:3017-23.
17. Younossi ZM, Gramlich T, Matteoni CA, et al. Nonalcoholic fatty liver disease in patients with type 2 diabetes. Clin Gastroenterol Hepatol 2004;2:262-5.
18. Stepanova M, Clement S, Wong R, et al. Patients with diabetes and chronic liver disease are at increased risk for overall mortality: A population study from the United States. Clin Diabetes 2017;35:79-83.
19. Younossi ZM, Otgonsuren M, Venkatesan C, et al. In patients with nonalcoholic fatty liver disease, metabolically abnormal individuals are at a higher risk for mortality while metabolically normal individuals are not. Metabolism 2013;62:352-60.
20. Targher G, Arcaro G. Non-alcoholic fatty liver disease and increased risk of cardiovascular disease. Atherosclerosis 2007;191:235-40.
21. Motamed N, Rabiee B, Poustchi H, et al. Non-alcoholic fatty liver disease (NAFLD) and 10-year risk of cardiovascular diseases. Clin Res Hepatol Gastroenterol 2016;41:31-8.
22. Ballestri S, Lonardo A, Bonapace S, et al. Risk of cardiovascular, cardiac and arrhythmic complications in patients with non-alcoholic fatty liver disease. World J Gastroenterol 2014;20:1724-45.
23. CDC. National Cancer for Health Statistics. National Health and Nutritional Examination Survey: Analytic guidelines. http://www.cdc. gov/nchs/nhanes/nh3data.htm. Hyatsville (MD): US Department of Health and Human Services, Centers for Disease Control and Prevention. [Accessed May 14, 2014]
24. CDC. National Center for Health Statistics. National Health and Nutrition Examination Survey: Procedure Manual, Hepatic steatosis (Nov 2010), Hyattsville(MD): US Department of Health and Human Services, Centers for Disease Control and Prevention http://www.cdc. gov/nchs/nhanes/nhanes3/HGUHSSE.htm. [Accessed May 14, 2014].
25. Lee K, Otgonsuren M, Younoszai Z, et al. Association of chronic liver disease with depression: A population-based study. Psychosomatics 2013;54:52-9.
26. CDC. Comperative analysis of the NHANES III public-use and restricted-use linked mortality files: 2010 public-use data release. National Center for Health Statistics. March 2010. Hyattsville, Maryland. http://www.cdc.gov/nchs/data/datalinkage/nhanes3-mort-compar e-2010-final.pdf. [Accessed May 14, 2014].
27. Paschos P, Paletas K. Non alcoholic fatty liver disease and metabolic syndrome. Hippokratia 2009;13:9-19.
28. Reccia I, Kumar J, Akladios C, et al. Non-alcoholic fatty liver disease: A sign of systemic disease. Metabolism 2017;72:94-108.
29. Dietrich P, Hellerbrand C. Non-alcoholic fatty liver disease, obesity and the metabolic syndrome. Best Pract Res Clin Gastroenterol 2014;28:637-53.
30. Yki-Jarvinen H. Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome. Lancet Diabetes Endocrinol 2014;2:901-10.
31. Kotronen A, Yki-Jarvinen H. Fatty liver: A novel component of the metabolic syndrome. Arterioscler Thromb Vasc Biol 2008;28:27-38.
32. Smits MM, Ioannou GN, Boyko EJ, et al. Non-alcoholic fatty liver disease as an independent manifestation of the metabolic syndrome: Results of a US national survey in three ethnic groups. J Gastroenterol Hepatol 2013;28:664-70.
33. Karajamaki AJ, Bloigu R, Kauma H, et al. Non-alcoholic fatty liver disease with and without metabolic syndrome: Different long-term outcomes. Metabolism 2017;66:55-63.
34. Firneisz G. Non-alcoholic fatty liver disease and type 2 diabetes mellitus: The liver disease of our age World J Gastroenterol 2014;20:9072-89.
35. Otgonsuren M, Stepanova M, Gerber L, et al. Anthropometric and clinical factors associated with mortality in subjects with nonalcoholic fatty liver disease. Dig Dis Sci 2013;58:1132-40.
36. Ong JP, Pitts A, Younossi ZM. Increased overall mortality and liverrelated mortality in non-alcoholic fatty liver disease. J Hepatol 2008;49:608-12.
37. Adams LA, Harmsen S, St Sauver JL, et al. Nonalcoholic fatty liver disease increases risk of death among patients with diabetes: A community-based cohort study. Am J Gastroenterol 2010;105: 1567-73.
38. Patil R, Sood GK. Non-alcoholic fatty liver disease and cardiovascular risk. World J Gastrointest Pathophysiol 2017;8:51-8.
39. Sung KC, Ryan MC, Wilson AM. The severity of nonalcoholic fatty liver disease is associated with increased cardiovascular risk in a large cohort of non-obese Asian subjects. Atherosclerosis 2009;203:581-6.
40. Brea A, Puzo J. Non-alcoholic fatty liver disease and cardiovascular risk. Int J Cardiol 2013;167:1109-17.
41. Gastaldelli A, KozakovaM, Hojlund K, et al. Fatty liver is associated with insulin resistance, risk of coronary heart disease, and early atherosclerosis in a large European population. Hepatology 2009;49:1537-44.
42. VanWagner LB, Wilcox JE, Colangelo LA, et al. Association of nonalcoholic fatty liver disease with subclinical myocardial remodeling and dysfunction: A population-based study. Hepatology 2015;62:773-83.
43. Oni ET, Agatston AS, Blaha MJ, et al. A systematic review: Burden and severity of subclinical cardiovascular disease among those with nonalcoholic fatty liver; should we care Atherosclerosis 2013;230:258-67.
44. Anstee QM, Targher G, Day CP. Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. Nat Rev Gastroenterol Hepatol 2013;10:330-44.
45. Vanni E, Marengo A, Mezzabotta L, et al. Systemic complications of nonalcoholic fatty liver disease: When the liver is not an innocent bystander. Semin Liver Dis 2015;35:236-49.
46. Ekstedt M, Hagstrom H, Nasr P, et al. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology 2015;61:1547-54.
47. DeFilippis AP, Blaha MJ, Martin SS, et al. Nonalcoholic fatty liver disease and serum lipoproteins: The Multi-Ethnic Study of Atherosclerosis. Atherosclerosis 2013;227:429-36.
48. Chatrath H, Vuppalanchi R, Chalasani N. Dyslipidemia in patients with nonalcoholic fatty liver disease. Semin Liver Dis 2012; 32:22-9.